65 results about "Papilloma virus" patented technology

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

The invention relates to a quadruple TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) primer group and a probe group for simultaneously detecting cGPV (Complementary Glutathione Virus), MDPV (Minimal Disease Papilloma Virus), MDGPV (Minimal Disease Papilloma Virus) and SBDSV (Sequence Broadcast DSV) and a kit thereof. The sequences of the primer group and the probe group are respectively shown as SEQ ID NO.1-12. The research successfully develops and verifies a multiple TaqMan-MGB real-time fluorescent PCR method capable of simultaneously detecting and distinguishing four important waterfowl parvoviruses (cGPV, MDPV, MDGPV and SBDSV). The method has good specificity, repeatability and high sensitivity. Compared with a conventional PCR method, the multiple detection method has the advantages that the clinical waterfowl parvovirus detection rate is remarkably improved, mixed infection can be effectively recognized, and the clinical diagnosis efficiency is greatly improved.

Methods for treating human papillomavirus (HPV) type 16- or HPV type 18-associated high-grade squamous intraepithelial lesions (HSIL) of the cervix are described

The present disclosure provides 3,7-disubstituted 2-oxo-2H-chromenyl compounds of Formula I or Formula II as inhibitors of helicases, such as SF3 and / or SF6 helicases, and more particularly, for example, CMG helicase and HPV El helicase, useful in treating medical disorders such as cancers or papilloma virus infections, as well as methods of making and using said compounds.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The invention relates to the technical field of skin care, and discloses pure plant compound liquid for removing warts and repairing a skin cuticle barrier and a preparation method of the pure plant compound liquid. The compound liquid is prepared by compounding a purslane extract, a brucea javanica extract, a honeysuckle extract, a licorice extract, an aloe extract, hyaluronic acid, glycerin, menthol and deionized water according to specific parts by weight. The preparation method comprises the steps of raw material pretreatment, basic liquid preparation, active ingredient addition, seasoning and homogenization, filtration and sterilization and the like. Whole plant extracts are adopted as core active ingredients, the synergistic effect of resisting viruses, removing warts, resisting inflammation and repairing skin barriers is achieved through scientific compounding, the activity of human papilloma viruses can be efficiently inhibited, wart shedding is promoted, damaged cuticles can be repaired, and skin resistance can be enhanced; the product is free of chemical preservatives and corrosive components, high in safety, small in irritation, suitable for various skin types, simple in preparation process and suitable for industrial large-scale production.

The invention discloses an mRNA (messenger Ribonucleic Acid) quality control product of human papilloma virus as well as a preparation method and application thereof, and belongs to the technical field of in-vitro diagnosis quality control. The method comprises the following steps: chemically synthesizing an HPV E6 / E7 gene DNA sequence, respectively cloning the HPV E6 / E7 gene DNA sequence into a cloning vector to construct a synthetic plasmid template, further preparing a nucleic acid fragment containing E6 / E7 mRNA through in-vitro transcription, carrying out absolute quantification through a digital PCR technology, mixing the nucleic acid fragment with human cervical cancer cell line RNA without any HPV sequence, and screening to obtain the HPV E6 / E7 gene DNA sequence. And the mRNA quality control product with stable structure and accurate value is prepared through a vacuum freeze drying technology. The quality control product can simulate HPV E6 / E7 mRNA in a clinical sample, has comprehensive types, is suitable for accurate evaluation of sensitivity, specificity, precision and other analysis performances of an HPV E6 / E7 mRNA detection kit, provides a key quality control tool for accurate risk stratification of cervical cancer, and is suitable for various detection platforms.

The invention belongs to the field of preparation of high-antibacterial carbon dots, and discloses a high-antibacterial carbon dot, a preparation process and application of the high-antibacterial carbon dot in vaginal gel. The prepared carbon dots are prepared by adopting physical shearing and ultrasonic synergistic pretreatment, then cooperating with microwave gradient energy crushing and stripping, and then performing centrifugation, dialysis purification and vacuum freeze drying, the damage of oxidation or acid treatment to a graphite structure is avoided in the whole process, and the carbon dots have excellent antibacterial and antiviral performance, can effectively inactivate various pathogenic microorganisms, and have good application prospects. Comprise herpes simplex virus, human papilloma virus HPV16, staphylococcus aureus, candida albicans and the like. The invention also optimizes application conditions, is suitable for developing efficient and safe vagina antibacterial gel products, and provides an innovative solution for preventing and treating gynecological infection.

The invention relates to a method, uses, a system, and a kit for detecting a human papillomavirus (HPV) genotype associated with the development of cervical, oral, or anogenital cancer in a subject and for determining the HPV genotype or genotypes thus detected in the same. Additionally, the present invention relates to uses of direct and / or reverse amplicons or primers generated by multiplex real-time PCR comprising a molecular tag for identifying a marker of human papillomavirus genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and / or 68.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

The invention provides a therapeutic papilloma virus mRNA vaccine and application thereof. The invention provides mRNA molecules as shown in SEQ ID NO: 57-89, and the mRNA molecules can enhance T cell activation and immunogenicity, stimulate an organism to generate TH1 type cellular immune response and increase the tumor inhibition rate.

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV6 and HPV11-associated recurrent respiratory papillomatosis (RRP).

The application belongs to the technical field of detection, and relates to a human papilloma virus detection reagent and application thereof. The human papilloma virus detection reagent comprises human papilloma virus antigen coated magnetic microparticle reagent and alkaline phosphatase labeled human papilloma virus antibody reagent. The human papilloma virus antigen coated magnetic microparticle is sealed by a sealing agent which is mixed by 2-10wt% PEG6000 solution, DB1130 and 0.1-1wt% gelatin solution. The system for detecting human papilloma virus antibody adopted by the application fills the gap of domestic HPV chemiluminescence antibody detection, and has high sensitivity, accuracy and clinical value.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and / or ameliorating a papillomavirus infection.

Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and / or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and / or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:

The present application belongs to the field of biomedical technology, and relates to a human papilloma virus (HPV) infection immune response related detection method and application. The present application provides a new method for detecting HPV infection, which comprises detecting virus load, DC maturation state in peripheral blood, or T lymphocyte subgroups and NK cell surface markers. The present application adopts a combined detection technology of DC cells, T lymphocytes and NK cells, and is used for detecting the immune response state of a host after HPV infection. The present application also provides application of the detection method. The detection method of the present application is simple and clear in result, and can be applied to clinical auxiliary detection and examination of HPV and even cervical cancer, and screening of HPV and even cervical cancer.

Disclosed herein is an immunotherapy for human papillomavirus. More particular, disclosed is a therapeutic composition that includes one or more polypeptides that comprise a plurality of epitopes derived from multiple human papillomavirus antigens, which, when used in immunotherapy is capable of eliciting a protective and durable cell mediated immune response, without being limited thereto. Also disclosed are methods of treating or preventing HPV and / or cancer.

The present invention provides a primer-probe combination for detecting HPV and / or HPV typing, belonging to the field of human papillomavirus (HPV) detection technology. The primer-probe combination includes one or more of HPV16E7, HPV18E7, HPV31E7, HPV45E7, HPV33E7, HPV35E7, HPV59E6, HPV68E6, HPV58E7, HPV51E6, HPV52E7, HPV56E6, HPV66E6, and HPV39E6, and can distinguish different types of HPV, with good specificity, accuracy, and low detection limit. The present invention uses a digital PCR method (dPCR) to detect the fluorescent signal of each droplet, and calculates the copy number of the target gene fragment in the entire reaction system based on the Poisson distribution principle, so that absolute quantification can be achieved without relying on a standard curve.

The present invention relates to a human papillomavirus antigen peptide and its application, belonging to the technical field of immunomedicine. The antigen peptide comprises the amino acid sequence shown in SEQ ID NO.1, or a small peptide having more than 90% similarity to the amino acid sequence shown in SEQ ID NO.1. The above-mentioned human papillomavirus antigen peptide is a new target located in the E7 gene of the HPV16 genome. This target is not expressed in normal human tissues during viral genome expression and can be used as an antigen target for applications in reagents, drugs, or vaccines for the diagnosis, treatment, and prognosis determination of clinical HPV16 / 18 infections or HPV16 / 18-positive tumors such as cervical cancer, esophageal cancer, head and neck cancer, oropharyngeal cancer, anogenital cancer, etc. For example, through adoptive T cell immunotherapy, it may bring new treatment possibilities to patients with advanced recurrent cervical cancer.

Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and / or treating infection with human papillomavirus type 6 and / or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.[In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]

The present invention provides a monoclonal antibody that specifically recognizes the L1 protein (HPV11 L1) and / or VLP (HPV11 VLP) of human papillomavirus type 11. The specific monoclonal antibody provided by the present invention has no significant cross-reactivity with the L1 proteins and / or VLPs of eight other HPV types (HPV6, 16, 18, 31, 33, 45, 52, and 58), and exhibits high specificity, sensitivity, accuracy, and safety. It can be used to accurately detect the bioactive content of HPV11 L1 protein and / or VLP in vaccine strains and is expected to be widely used in clinical testing and vaccine production.

The invention discloses a plant composite antibacterial liquid composition aiming at HPV (human papillomavirus) infection and a preparation method thereof, and belongs to the technical field of biological medicines. The composition is prepared from the following components in parts by weight: 5 to 20 parts of brucea javanica extract, 3 to 15 parts of senna extract, 2 to 10 parts of anhydridized beta-lactoglobulin, 1 to 8 parts of dandelion extract, 1 to 5 parts of penetration enhancer, 0.1 to 1 part of pH (Potential of Hydrogen) regulator, 0.1 to 0.5 part of preservative and the balance of phosphate buffer solution. According to the invention, anhydridized beta-lactoglobulin is innovatively taken as a carrier, so that targeted delivery of active ingredients is realized; the anti-HPV effect is enhanced through the synergistic effect of the brucea javanica and the kalii extract; the anti-inflammatory repair function of the dandelion extract is combined, and a compound penetration enhancer and a specific preparation process are matched, so that the product has the characteristics of efficient HPV resistance, anti-inflammatory repair, mildness, no irritation and good stability.

The application discloses a recombinant protein of human papillomavirus type 52 L1 protein, and the amino acid sequence of the recombinant protein is the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) with a His tag at the N terminal, wherein the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) is shown as SEQ ID NO:1; the recombinant protein is applied to preparation of a reagent for detecting human papillomavirus type 52 infection, and can be used for detecting whether HPV52 antibodies exist in a vaginal washing liquid of a to-be-detected person; the method has the characteristics of high sensitivity and specificity, wide application, and is not dependent on large equipment, and has strong universality.

The invention relates to a device in the field of fractional ablation of cervical epithelium for the treatment of papilloma virus, cervical interepithelial neoplasia and cervix cancer.

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

This invention relates to antisense oligonucleotides targeting different subtypes of human papillomavirus (HPV) oncogenes and their applications. The ASO molecules are 14–40 bases in length and specifically pair with specific regions of target genes. This invention also relates to the following applications of the ASO molecules: (1) preparing preparations to inhibit HPV virus expression; or (2) preparing drugs or drug compositions for treating diseases related to HPV infection; or (3) treating diseases related to HPV infection; or (4) inhibiting the expression of HPV virus genes.

The invention belongs to the technical field of medical animal model construction, and particularly relates to a construction method of an animal model for simulating various stages from HPV (human papillomavirus) continuous infection to cervical canceration in a natural infection state and application of the animal model. According to the method, a drug immunosuppressor for promoting HPV infection is combined with MmuPV1 for mouse lower genital tract infection modeling; the constructed animal model is stable and uniform in papilloma virus infection, high in modeling rate, low in fatality rate, short in modeling time, controllable in process and good in reproducibility, can completely reproduce the whole process from HPV continuous infection to cervical canceration, accords with clinical practice, improves the efficiency and quality of model construction, and is suitable for popularization and application. An ideal animal model is provided for follow-up research on an HPV infection carcinogenic mechanism and a virus host interaction mechanism, meanwhile, the model can assist in research, development and screening of clinical treatment methods for preventing and treating cervical lesions at all stages, and clinical transformation, new drug research and development and other work are promoted.

The utility model discloses a sampling test tube for human papilloma virus inhibitor detection and analysis, which comprises a test tube body, the outer surface of the test tube body is fixedly connected with a connecting table at the upper edge position, the bottom end of the connecting table is in threaded connection with a protective jacket, and the outer surface of the protective jacket is fixedly communicated with an exhaust tube. And the bottom end of the exhaust pipe fixedly communicates with an adjusting pipe. Through the arrangement of the protective jacket, the test tube body can be effectively protected, so that the test tube body can be effectively prevented from being directly damaged when collision occurs, the service life is prolonged, and furthermore, a vacuum pump can be connected with an exhaust pipe to extract air between the test tube body and the protective jacket to form a vacuum environment; a sample in the test tube body is difficult to be interfered by external air temperature, and the quality of the sample is improved.

The invention relates to a recombinant bioactive protein for preventing or treating human papilloma virus infection as well as a preparation method and application thereof, and belongs to the technical field of medicines. The recombinant bioactive protein disclosed by the invention is anhydridized recombinant lactoferrin, anhydridized recombinant lactoglobulin or anhydridized recombinant histone; the recombinant bioactive protein is obtained by carrying out anhydridation modification on recombinant lactoferrin, recombinant lactoglobulin or recombinant histone by using 3-hydroxyphthalic anhydride or a derivative thereof, 4-hydroxyphthalic anhydride or a derivative thereof, succinic anhydride or maleic anhydride. The bioactive protein disclosed by the invention has the advantages of preventing HPV virus from invading cells, preventing virus from expanding infection, resisting bacteria and oxidation, being safe, stable, convenient to store and transport, low in cost and the like.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.